Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01061411
Recruitment Status : Completed
First Posted : February 3, 2010
Last Update Posted : April 26, 2017
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Roswell Park Cancer Institute

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : October 14, 2015
  Study Completion Date : April 21, 2017